Vivani Medical posts investor deck outlining NanoPortal ultra-long-acting GLP-1 implant strategy for obesity market

Reuters2026/08/17 20:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vivani outlined its NanoPortal ultra-long-acting subdermal GLP-1 implant platform targeting once- or twice-yearly dosing for chronic weight management.
Lead candidate NPM-139, a semaglutide implant, is in SLIM-1 with top-line data expected in Nov 2026.
Phase 2 study design is underway with an anticipated 2027 start for NPM-139.
Cash runway is expected to fund the current operating plan through 1H2027, including completion of key milestones.
The deck cited $132 billion in 2025 global sales for FDA-approved GLP-1 products, with high discontinuation rates by year 1 and year 2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vivani Medical posts investor deck outlining NanoPortal ultra-long-acting GLP-1 implant strategy for obesity market

You may also like

Crypto prices